<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00314977</url>
  </required_header>
  <id_info>
    <org_study_id>IKO 2005-01 / BOOG 2007-02</org_study_id>
    <nct_id>NCT00314977</nct_id>
  </id_info>
  <brief_title>Sequential vs Upfront Intensified Neoadjuvant Chemotherapy in Patients With Large Resectable or Locally Advanced Breast Cancer.</brief_title>
  <acronym>INTENS</acronym>
  <official_title>Sequential vs Upfront Intensified Neoadjuvant Chemotherapy in Patients With Large Resectable and/or Locally Advanced Breast Cancer. The INTENS Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      2 different treatment schedules may be used for neoadjuvant chemotherapy in breast cancer
      using adriamycin, cyclophosphamide and taxotere. The most optimal sequence- concurrent or
      sequential- is however unclear. The aim of the study is to compare the efficacy and
      tolerability of neoadjuvant chemotherapy with AC followed by T(adriamycin, cyclophosphamide,
      taxotere) versus TAC ( with upfront T) in patient with large resectable or locally advanced
      breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The pathologic complete response rate to neoadjuvant chemotherapy.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The delivered chemotherapy dose and dose-intensity of both chemotherapy regimens</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The tolerability (grade 3/4 CTC toxicities) of both chemotherapy regimens.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The clinical responses of neoadjuvant chemotherapy correlated to pathological responses after neoadjuvant chemotherapy.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The value of breast MRI in evaluating response to neoadjuvant chemotherapy as compared to clinical palpation, ultrasound techniques and histo-pathological outcome.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The false-negative rate of the sentinel node biopsy after neoadjuvant chemotherapy.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The disease-free and overall survival after 3 and 5 years follow-up.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The relation between pCR and DFS/OS.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The feasibility of the criteria for reporting pathological tumour response in surgical breast and axillary node resection specimens.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The prognostic and predictive value of tumour- and molecular markers, including ER, PgR, c-erbB2, microarray and other tumour characteristic analyses.</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycles 1-4 q 3 weeks: doxorubicin plus cyclophosphamide Cycles 5-8 q 3 weeks: docetaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycles 1-6 q 3 weeks: doxorubicin, cyclophosphamide and docetaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>doxorubicin (arm A:60 mg/m2) and arm B: 50 mg/m2)</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>hydroxyldaunorubicin</other_name>
    <other_name>adriamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide: (arm A; 6000 mg/m2) an (arm B: 500 mg/m2)</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel: (arm A: 100 mg/m2) and (arm B: 75 mg/m2)</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women presenting with large resectable or locally advanced breast cancer (T2 ≥3 cm,
             T3, or T4, and/or LN positive)

          -  Measurable disease (breast and/or lymph nodes)

          -  No prior surgery other than biopsy and no prior chemotherapy or radiation therapy

          -  Age ≥18 years and age ≤70 years

          -  Karnofsky Performance score ≥70%

          -  Estrogen and/or progesterone receptor analysis performed on the primary tumour in the
             biopsy material

          -  In case the tumor is ER/PgR ³ 50% positive, (neo)adjuvant hormonal therapy in stead of
             chemotherapy should be considered (e.g. in TEAM II study)

          -  Her2/neu receptor analysis performed on the primary tumour in the biopsy material

          -  Adequate bone marrow function (within 14 days prior to registration): WBC ≥3.0 x
             109/l, neutrophils ≥1.5 x 109/l, platelets ≥100 x 109/l

          -  Adequate liver function (within 4 weeks prior to start treatment): bilirubin ≤1.5 x
             upper limit of normal (UNL) range, ALAT and/or ASAT ≤2.5 x UNL, Alkaline Phosphatase
             ≤5 x UNL

          -  Adequate renal function (within 4 weeks prior to start treatment): the calculated
             creatinine clearance should be ≥50 mL/min

          -  Patients must be accessible for treatment and follow-up

          -  Written informed consent according to the local Ethics Committee requirements

        Exclusion Criteria:

          -  Patients with advanced pulmonary disease of any cause (oxygen dependent)- Peripheral
             neuropathy &gt; grade 2 whatever the cause

          -  Serious other diseases as recent myocardial infarction, clinical signs of cardiac
             failure or clinically significant arrythmias

          -  Evidence of distant metastases (M1)

          -  Patients with a history of breast cancer

          -  Patients with a history of another malignancy (except basal cell skin carcinoma and
             carcinoma-in-situ of the uterine cervix) within 5 years of study entry- Pregnant or
             lactating women, or potentially fertile women not using adequate contraception
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>V.C.G. Tjan-Heijnen</last_name>
    <role>Principal Investigator</role>
    <affiliation>AZM Maastricht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rijnstate Ziekenhuis</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HAGA Ziekenhuis</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deventer Ziekenhuis</name>
      <address>
        <city>Deventer</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slingeland Hospital</name>
      <address>
        <city>Doetinchem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Anna Hospital</name>
      <address>
        <city>Geldrop</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jansdal Ziekenhuis</name>
      <address>
        <city>Harderwijk</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atrium Medisch Centrum</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elkerliek Ziekenhuis</name>
      <address>
        <city>Helmond</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spaarne Ziekenhuis</name>
      <address>
        <city>Hoofddorp</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum (LUMC)</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academical Hospital Maastricht (AZM)</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canisius Wilhelmina Ziekenhuis</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waterland Hospital</name>
      <address>
        <city>Purmerend</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maasland Hospital</name>
      <address>
        <city>Sittard</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elisabeth Ziekenhuis</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mesos Medisch Centrum</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum</name>
      <address>
        <city>Veldhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zaans Medical Centre</name>
      <address>
        <city>Zaandam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2006</study_first_submitted>
  <study_first_submitted_qc>April 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2006</study_first_posted>
  <last_update_submitted>March 17, 2010</last_update_submitted>
  <last_update_submitted_qc>March 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof dr V.C.G. Tjan-Heijnen</name_title>
    <organization>Maastricht University Medical Center</organization>
  </responsible_party>
  <keyword>Large resectable breast cancer</keyword>
  <keyword>Locally advanced breast cancer</keyword>
  <keyword>Neoadjuvant therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

